Strides Arcolab gets USFDA nod for generic skin disease cream

Tags: Companies
Drug firm Strides Arcolab has received approval from the US health regulator to market its generic Imiquimod cream, used in treating skin diseases, in the American market.

The Bangalore-based company has received approval from the US Food and Drug Administration (USFDA) for Imiquimod cream, Strides Arcolab Ltd said in a statement.

"This is the first product approval from Beltapharm, the company's USFDA approved semi-solids facility in Milan, Italy. The product will be marketed directly by Strides in the US market," it added.

According to IMS data, the US market for generic Imiquimod cream is around USD 140 million.

Imiquimod cream is a topical skin cream indicated for the treatment of certain types of actinic keratoses (precancerous skin lesions) on the face or scalp, external genital and perianal warts in patients aged 12 years and more.

Strides shares were trading at Rs 624.75 apiece on the BSE, up 3.46 per cent from its previous close.

EDITORIAL OF THE DAY

  • Time for a reality check on AIDS

    Is the fear of Human Immuno-deficiency Virus (HIV) infection leading to Acquired Immuno-deficiency Syndrome (AIDS) in India?

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

<b>Disequilibrium:</b> The Looking glass war

In the looking glass war, where bitter adversaries - Ratan ...

Ananda Majumdar

<b>Ruminations:</b> How JP can wake up Cong

The Congress party has clearly missed a trick with its ...

Sachin Shridhar

The quagmire called kashmir

For the past three decades, the separatist leaders have claimed ...